22 drugs fabrished in China were withdrawn from the Moldovan pharmaceutical market. This is because the European Medicines Agency has issued a warning following the identification of potentially carcinogenic impurities in the active substance Valsartan.

The Medicines Agency has withdrawn all preparations containing this substance.

According to the institution, there are 28 other medicinal products containing Valsartan, which are manufactured by other manufacturers and contain no high-risk impurities for health, in the State Nomenclature.

These preparations are used to treat heart disease.